Request for Proposals

2026 ASTRO Radiation Oncology Resident Fellowship

PROGRAM PARTNER	AstraZeneca Pharmaceuticals LP (AstraZeneca)
POSTED DATE	May 18, 2026
DUE DATE	June 29, 2026; 11:59 PM Eastern Standard time (GMT -5)
EARLIEST START DATE	August 1, 2026
AWARD TERM	One year (August 1, 2026, to July 31, 2027)
NUMBER OF AWARDS	One
PURPOSE	The 2026 ASTRO Resident Fellowship program will provide a radiation oncology resident (PGY-3 or later) with funding for research and the professional development opportunity of a one-year assignment working part-time and remotely with colleagues at AstraZeneca. This captures the benefits of working with industry while allowing residents to meet the requirements of their residency programs. This program is supported by an educational grant from AstraZeneca.
PROGRAM FORMAT	The Fellow will lead a one-year research project at the Fellow's home institution with a local mentor. Research proposals will be analogous to those requested through the 2026 ASTRO Radiation Oncology Resident Fellowship with an emphasis on the intersection of radiation oncology and immuno-oncology (IO) in non-small cell lung cancer (NSCLC). A presentation on research progress will be made by the Fellow to AstraZeneca staff upon completion of the Fellowship. The Fellow will commit at least one eight-hour day per week for one year to remote work with AstraZeneca, with flexibility to adjust their schedule as mutually agreed upon by the Fellow, the Fellow's residency program director, and AstraZeneca. The approximate work schedule will be negotiated before the Fellowship begins, and exceptions accommodated as needed without sacrificing residency training time. Funding will be available to reimburse limited travel to AstraZeneca sites. The Fellow is encouraged to present their research findings at the ASTRO Annual Meeting and can be reimbursed for travel expenses to

	participate therein. The Fellow will receive a small honorarium and will not receive research support directly.
SCOPE OF RESEARCH	The scope of research must be focused on the intersection of SBRT or hypofractionated radiotherapy with IO in early stage non-small cell lung cancer.
AWARD BUDGET	$50,000 is available for the one-year research project. The Fellow will also receive a $5,000 honorarium. No indirect costs are allowed. Additional funds available include: • Up to $25,000 to reimburse the Fellow's lodging and travel to AstraZeneca sites. All unused funds are retained by ASTRO and refunded to AstraZeneca. • Up to $5,000 to reimburse the Fellow's lodging and travel to present findings at an ASTRO Annual Meeting. All unused funds are retained by ASTRO and refunded to AstraZeneca.
PROGRAM CONTACT	Email questions about this opportunity to the Department of Scientific Affairs at science@astro.org. Technical questions about the ProposalCentral submission system should be directed to their customer support at 1-800-875-2562 (Tollfree U.S. and Canada) or by email pcsupport@altum.com. Support is available during normal business hours: 8:30 am - 5:00 pm Eastern Time (Monday through Friday).

ELIGIBILITY

ASTRO has full discretion in any funding decision and is not obligated nor liable to issue any award to any eligible or ineligible applicants at any time.

Eligible Organizations

Higher Education Institutions

- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education

Nonprofits Other Than Institutions of Higher Education

- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

Foreign Institutions

- Non-domestic (non-U.S.) Entities (Foreign Institutions) are **not** eligible to apply.
- Non-domestic (non-U.S.) components of U.S. Organizations are **not** eligible to apply.

Eligible Individuals (Residents/Fellows)

Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Principal Investigator (PI) is invited to work with their mentor(s) and organization to develop an application for support. **Multiple PIs are not allowed.**

- Fellows must hold a medical degree such as M.D./Ph.D., M.D., D.O., or other equivalent degrees(s).
- Fellows must be at least postgraduate year three (PGY-3) as of August 1, 2026 and must not complete their training before July 31, 2027. Applicants who previously graduated from a radiation oncology residency program yet currently maintain a trainee status (such as a postdoctoral training appointment or an advanced degree program) at an eligible institution and will maintain this status until a date after July 31, 2027 are also eligible. Faculty members or those with equivalent status are **not** eligible to apply.
- Fellows must work in the fields of radiation oncology, radiation or cancer biology, or radiation physics. Strong clinical experience, including clinical research experience, is highly desired.
- Level of effort: Fellows are required to commit at least 50% of their research efforts to the proposed project. The remainder of time may be devoted to clinical or other pursuits consistent with the objectives of the grant.

COMMITMENT FROM THE APPLICANT

- Fellows must designate a mentor at their Institution who will provide guidance and support for the research project. Mentors should be senior investigators. They must provide a letter of support detailing their oversight and support.
- The Fellow should develop, with the mentor, a career development plan that is consistent with their previous training and suited to their career development needs.
- The Fellow will also be assigned an AstraZeneca mentor who will oversee fellowship activities.
- The Fellow must work with their residency program director and the AstraZeneca mentor to agree on a general remote working schedule.
- The Fellow will keep their residency program director informed of any changes in their remote work schedule with AstraZeneca. The Fellow will keep their residency program director informed of any proposed travel to AstraZeneca sites.

- The Fellow will make every effort to attend at least one ASTRO Annual Meeting to present their research findings.
- The Fellow is required to contact ASTRO immediately if any problems are encountered that would prevent them from successfully completing the fellowship.

COMMITMENT FROM THE APPLICANT'S MENTOR

- The mentor will be an accomplished investigator in the proposed research area and have a track record of success in training independent investigators.
- The mentor should have sufficient independent research support to cover the costs of the proposed research project in excess of the allowable costs of this award.
- The mentor will approve of the Fellow's proposed career development plan.
- The mentor must demonstrate, in writing, a commitment to the development of the applicant as a productive, independent investigator.
- Applicants may also nominate co-mentors as appropriate to the goals of the program.

COMMITMENT FROM THE APPLICANT'S RESIDENCY PROGRAM DIRECTOR

- The residency program director must demonstrate, in writing, a commitment to the development of the applicant as a productive, independent investigator. It is expected that the Fellow will update the residency program director to any changes in scheduling of remote work time.
- The residency program director will approve travel requests to AstraZeneca sites when/if the Fellow is invited for in-person site visits.

COMMITMENT FROM THE APPLICANT'S INSTITUTION

- The Terms & Conditions for this Award are attached and should be shared with organizational officials before applications are submitted.
- If awarded, the host department will act as the fiscal intermediary. The Institution will administer the research funds (up to $50,000), as well as distribute the Fellow's honoraria ($5,000) as agreed to in the Terms of the Award, and be responsible for satisfying tax withholding, deposit and/or reporting requirements applicable to the payment of the research award. The Fellow will be responsible for individual income taxes.
- The Fellow's institution will maintain insurance for medical professional liability and comprehensive general liability during the Fellowship period.
- The Institution will be required to provide sufficient additional funds to supplement salaries or supplies as needed for the research project.

- Any change in Institution, mentor or in the applicant's position that might affect their ability to successfully complete their training or project should be communicated as soon as possible to ASTRO so that appropriate action can be taken.
- When a mentor at the Fellow's Institution is to be replaced, the Institution must submit a letter from the proposed mentor documenting: 1) the need for substitution; 2) the new mentor's qualifications for supervising the project; and 3) the level of support for the applicant's career development.
- Only one (1) grant can support the proposed research project. If independent funding is obtained for the same scope of work selected by ASTRO for this award, the recipient must refuse either this or the competing award(s).

USE OF ARTIFICIAL INTELLIGENCE IN PROPOSALS AND PEER REVIEW

- **Applicants:** A large language model, such as ChatGPT, or a generative artificial intelligence (AI) tool can be used to generate and/or edit content in research proposals submitted to ASTRO. This information must be disclosed at the time of submission. Disclosure of this information does not impact peer review. Should this information not be disclosed accurately, and use of these tools is identified, the proposal may be administratively withdrawn.
- **Peer Reviewers:** ASTRO does **NOT** permit the use of large language models, such as ChatGPT, or a generative AI tool to generate and/or edit content in the peer review process. Uploading any portion of a research proposal into a large language model or an AI tool to assist in writing a critique of the proposal is explicitly prohibited.

APPLICATION GUIDELINES

All applications are due by 11:59 pm Eastern time on June 29, 2026. Proposals will not be considered after the deadline. Applications must be submitted online using the application tool and document templates and requirements therein at ProposalCentral

Formatting

All materials **MUST** be prepared in English, single-spaced with normal spacing between letters and words, using a font style such as Arial or Times New Roman and font size between 10 and 12. A minimum of one-half inch margins must be used on all page borders.

Each section must be loaded into ProposalCentral. Applicants can stop at any point and save the application to be completed by the deadline.

Submission Content

All applications must contain the following:

1. **Abstracts:** A general audience abstract that can be published if the proposal is awarded (2,000 characters max, including spaces), a technical abstract (3,000

characters max), and a brief statement of the proposal's benefit to lung cancer and radiation oncology research (1,000 characters max) are required.

2. **Personal statement (Recommended length 2 pages**): A detailed personal statement that outlines the following:
    - Prior research and clinical experience
    - Dedication to work in radiation oncology
    - Intention for pursuing this Fellowship
    - Future professional goals and plans
3. **Research Plan (6-page limit)**: Project description to fit within the 1-year project period and should include:
    - Background
    - Preliminary data and figures (if applicable, but not required)
    - Specific aims
    - Experimental design/methods
    - Statistical analysis plan
    - Anticipated outcomes
    - Potential pitfalls and alternatives
    - Significance
    - Future directions
4. **Budget and Budget Justification**: Submit a detailed budget (can be prepared using the NIH budget form e.g., PHS 398) and Budget Justification with a breakdown and description of the estimated costs. ASTRO will cover only direct costs. Funding cannot go towards supporting salaries of mentors or collaborators.
5. **SciENcv (2)**: The Applicant and Mentor must each submit a PDF output of the NIH's SciENcv, including a list of relevant publications and currently funded research projects. SciENcv for collaborators and research support staff are not required.
6. **Career Development Plan (one-page limit)**: A plan that is consistent with the Applicant's previous training and suited to their career development needs during the fellowship period must be developed jointly by the applicant and the applicant's academic mentor(s). It can outline courses, lectures, meetings, and other ways to support the applicant and help increase likelihood of success.
7. **Letters of support (1 to 2):** One letter of support must be from the Applicant's Mentor. The second must be from the Applicant's Residency Program Director. Letters of support from additional collaborators can be appended but are not required. The research mentor may be the residency program director, and in this case only one letter of support is needed.

8. **Institutional letter of support:** Upload a letter of support from the Institution or Department. This letter must indicate the level of commitment through matching funds or in-kind contribution from the Institution to this award. This letter should include a guarantee that the applicant will be afforded at least 50 percent of their protected research time to perform research.
9. **Signatures**: Before submitting the application, complete all fields within the signature page. **Four electronic signatures are required. They are required from the Applicant/Fellow, the Mentor, the Residency Program Director, and a Signing Official from the applicant's institution.** Applications will not be considered for review if required electronic signatures are missing. The research mentor may be the residency program director, and in this case they will sign both fields.

Applications lacking the required content or in the incorrect format will be considered ineligible for review. Materials submitted after the deadline will not be accepted.

No additional data or documentation, such as accepted manuscripts or received awards, will be accepted.

APPLICATION REVIEW

All proposals will undergo a rigorous peer review by the ASTRO Grant Review Panel consisting of researchers with expertise in the areas and topics of each grant will review the application for scientific merit and appropriateness for funding. Reviewers are members of the ASTRO Scientific Review Panel**.** If no suitable candidates are found, no awards may be issued.

Review Criteria: In general, reviewers should evaluate the candidate's potential for making important contributions to the field of radiation oncology, taking into consideration the years of experience and the likely value of the proposed project as a vehicle for developing a successful, independent career. Selected proposals will have strong merit and impact, possess an innovative and transformative approach, and demonstrate potential for progression to the clinic or other significant impact.

Overall Impact

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the radiation oncology research field. In addition, Reviewers should provide their assessment of the likelihood that the proposed mentorship and research plan will enhance the candidate's potential for a productive, independent scientific research career, taking into consideration the criteria below in determining the overall impact score.

Scored Review Criteria

Reviewers will score (rate 1-9) Factor 1 and 2 and will determine whether Factor 3 is sufficient or insufficient.

Factor 1: Significance and Innovation

Significance

- Evaluate the importance of the proposed research in the context of current scientific challenges and opportunities, either for advancing knowledge within the field, or more broadly. Assess whether the application addresses an important gap in knowledge in the field, would solve a critical problem, or create a valuable conceptual or technical advance.
- Evaluate the rationale for undertaking the study, the rigor of the scientific background for the work (e.g., prior literature and/or preliminary data) and whether the scientific background justifies the proposed study.

Innovation

- Evaluate the extent to which innovation influences the importance of undertaking the proposed research. Note that while technical or conceptual innovation can influence the importance of the proposed research, a project that is not applying novel concepts or approaches may be of critical importance for the field.
- Evaluate whether the proposed work applies novel concepts, methods or technologies or uses existing concepts, methods, technologies in novel ways, to enhance the overall impact of the project.

Factor 2. Rigor and Feasibility

Approach. Evaluate the scientific quality of the proposed work. Evaluate the likelihood that compelling, reproducible findings will result (rigor) and assess whether the proposed studies can be done well and within the timeframes proposed (feasibility).

Rigor

- Evaluate the potential to produce unbiased, reproducible, robust data.
- Evaluate the rigor of experimental design and whether appropriate controls are in place.
- Evaluate whether the sample size is sufficient and well-justified.
- Assess the quality of the plans for analysis, interpretation, and reporting of results.
- Evaluate whether the investigators presented adequate plans to address relevant biological variables, such as sex or age, in the design, analysis, and reporting.
- For applications involving human subjects or vertebrate animals, also evaluate:
    - the rigor of the intervention or study manipulation (if applicable to the study design).
    - whether outcome variables are justified.
    - whether the results will be generalizable or, in the case of a rare disease/special group, relevant to the particular subgroup.

  - whether the sample is appropriate and sufficiently diverse to address the proposed question(s).

- For applications involving human subjects, including clinical trials, assess the adequacy of inclusion plans as appropriate for the scientific goals of the research. Considerations of appropriateness may include disease/condition/behavior incidence, prevalence, or population burden, population representation, and/or current state of the science.

Feasibility

- Evaluate whether the proposed approach is sound and achievable, including plans to address problems or new challenges that emerge in the work. For proposed studies in which feasibility may be less certain, evaluate whether the uncertainty is balanced by the potential for major advances.
- For applications involving human subjects, including clinical trials, evaluate the adequacy and feasibility of the plan to recruit and retain an appropriately diverse population of participants. Additionally, evaluate the likelihood of successfully achieving the proposed enrollment based on age, racial, ethnic, and sex/gender categories.
- For clinical trial applications, evaluate whether the study timeline and milestones are feasible.

Factor 3: Expertise and Resources.

- *Investigator.* Evaluate whether the investigator(s) have demonstrated background, training, and expertise, as appropriate for their career stage, to conduct the proposed work.
- *Environment.* Evaluate whether the institutional resources are appropriate to ensure the successful execution of the proposed work.

Additional Review Criteria:

As applicable for the project proposed, reviewers will consider the following additional items while determining scientific and technical merit and in providing an overall impact score, but will not give scores for these items:

Protections for Human Subjects

- For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: (1) risk to subjects, (2) adequacy of protection against risks, (3) potential benefits to the subjects and others, (4) importance of the knowledge to be gained, and (5) data and safety monitoring for clinical trials.
- For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: (1) the justification for the exemption, (2) human subjects involvement

and characteristics, and (3) sources of materials. For additional information on review of the Human Subjects section, please refer to the NIH Guidelines for the Review of Human Subjects.

- When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals across the lifespan (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the NIH Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

- The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the NIH Worksheet for Review of the Vertebrate Animal Section.

Biohazards

- Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Budget and Period of Support

- Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

OTHER INFORMATION

The *Terms and Conditions* for this award are attached to this Program Announcement as a reference for the institutional signing official.

American Society for Radiation Oncology (ASTRO)

2026 Radiation Oncology Resident Fellowship

Terms and Conditions

This document contains the Award Terms and Conditions ("Terms and Conditions") applicable to the ASTRO and its affiliates ("ASTRO") 2026 ASTRO Radiation Oncology Resident Fellowship ("Award"). Please read these Terms and Conditions carefully. By accepting the Award as set forth in the Award letter ("Award Letter"), both the Principal Investigator and the Institution acknowledge that they have read, understand, and agree to comply with the Terms and Conditions herein.

1. Conditions of the Award.

As a condition of receiving the Award granted in the Award Letter, the Principal Investigator ("Principal Investigator") acknowledges, and the Institution ("Institution") agrees (Institution and Principal Investigator are collectively defined as the "Recipient") to enter into an agreement to comply with the Terms and Conditions as follows ("Agreement").

(A) Compliance: Recipient shall perform the research ("Research") described in the submitted Research Proposal ("Research Proposal") in full compliance with (i) all applicable laws and regulations; (ii) the Request for Proposal ("RFP"); (iii) these Terms and Conditions, referenced herein or later modified with notice provided in writing per Section 1(D); (iv) the Award Letter; and (v) the Research Proposal.

(B) Approvals: Recipient shall obtain ASTRO's written approval prior to making any significant changes to the Research Proposal. In addition, Recipient shall promptly notify ASTRO in writing of any change in the individual(s) assigned to manage the project or those involved in the project as indicated in the Proposal, including if the individual designated as the Principal Investigator in the Award Letter (i) ceases to conduct the Research; (ii) is unable to continue to serve as the Principal Investigator; or (iii) departs from, or is otherwise no longer affiliated with the Institution named in the Award. Recipient shall fully comply with ASTRO's written instructions regarding the continuation of the Research Proposal.

(C) Progress Reports: Recipient shall provide ASTRO with a final written report, as set forth in the Reporting Schedule. Recipient will use the progress report form provided by ASTRO and grants ASTRO permission to review, use, and retain such reports, in whatever manner ASTRO chooses in its sole discretion. The reports shall include, at a minimum, the following (in addition to any other items reasonably requested in writing by ASTRO):

i. Summary of expenditures, activities, and findings from the performance of the Research Proposal during the year, including a financial statement related to the use of the funds and additional funding received from other sources. The responsible financial officer for the Institution must attest to the accuracy of any financial statements.

ii. List and copies of any work product produced during the performance of the Research

Proposal funded by the Award (including, without limitation, publications, presentations, conferences, research, findings and manuscripts) ("Work Product"), Award IP (as defined below), and any similar professional activities and outcomes supported by the Award. "Award IP" is defined as any patentable invention, discovery, improvement, and/or other product conceived and reduced to practice during the performance of the Research Proposal funded by the Award.

iii. Discussion of any collaborations with industry groups relating to the Research Proposal, if applicable.

All required reporting in this paragraph (C) should be submitted through ProposalCentral.

(D) Notices:

1. Recipient shall promptly notify ASTRO in writing if any item in the below list occurs, whether during the award period, or after:

   i. Findings, breakthroughs, or events of unusual interest funded with this Award.

   ii. Filing of an Invention Disclosure (or similar form) regarding any Award IP.

   iii. Any monetization event that occurs regarding Award IP or Work Product.

   iv. Problems, delays, or adverse conditions that will or may materially affect the Research Proposal, its objectives, or time schedules or budget, together with proposed Recipient actions to address such problems, delays, or adverse conditions.

   v. Expected or unexpected adverse events that negatively impacted the safety or wellbeing of any human or vertebrate animal subjects associated with the activities, as described in the Research Proposal.

   vi. Any expenditure from the Award made for any purpose other than those for which it was awarded.

2. All notices to the parties shall, unless otherwise modified in writing and acknowledged in writing by the other party, be sent to the following addresses:

   If to ASTRO/Speed of Light – the ASTRO Foundation:

   American Society for Radiation
   Oncology Attn: Scientific Affairs

   251 18th Street South, 8th Floor
   Arlington, VA 22202
   science@astro.org

   If to the Institution: (enter your information below)

Any such notice, communication or delivery will be deemed given upon receipt. Notices sent via email (return receipt requested) are deemed to be official notice.

2. Award Management and Payment.

(A) Distribution: Subject to each Recipient's submission of a signed copy of this Agreement and compliance with the Terms and Conditions required herein, ASTRO will distribute the Award as set forth in the RFP. The Award may only be used to fund the direct expenses of conducting the Research Proposal, and in no event may any portion of the Award be used for any indirect or overhead costs. Allowable costs for the Grant will be defined in the RFP. Payments will be disbursed through ACH.

(B) No Cost Extensions: Requests for extensions of time beyond the end date of the Award must be made to ASTRO in writing thirty (30) days prior to the end date of the Award and in compliance with ASTRO's written instructions. No additional funding will be made available for such extensions ("No Cost Extensions"). No Cost Extensions are granted on a case-by-case basis and in ASTRO's sole discretion. If a No Cost Extension is granted, ASTRO may request additional reporting from Recipient in connection with the Research Proposal similar to that reporting set forth in Section 1(C) above.

(C) Budget Deviations: Expenditures must adhere to the budget submitted to ASTRO by the Principal Investigator and included in the Research Proposal. In addition, expenditures must comply with the budget guidelines in the RFP and all applicable laws and regulations. Significant changes to the award budget requests are granted on a case-by-case basis in ASTRO's sole discretion.

(D) Restrictions on Use of Funds: In no event may the Award be used for any of the following purposes:

i. To attempt to influence legislation or the outcome of any specific public election;

ii. To carry on, directly or indirectly, any voter registration drive;

iii. To make, without ASTRO's written consent, grants to individuals or other organizations; or undertake any activities for other than a charitable, educational, or scientific purpose.

(E) Reporting Under the Physician Payment Transparency Program ("Open Payments"): To the extent that Recipient is a Covered Recipient subject to the Physician Payment Transparency Program ("Open Payments"), ASTRO has agreed to report payments made under this Award to AstraZeneca Pharmaceuticals LP ("AstraZeneca") for reporting to the Centers for Medicare and Medicaid Services under the Open Payments program.

(F) Award Closeout: At the end of the Award Period, the Institution shall refund any unspent portion of the Award to ASTRO within 30 days of the end of the Award Term (as defined in the Award Letter).

3. Confidentiality.

During the term of this Agreement, certain confidential information ("Confidential Information") may be disclosed by Recipient (including Principal Investigator or Institution) to ASTRO or by ASTRO to the Principal Investigator and/or Institution. Each Disclosing Party

agrees to clearly identify in writing any such information as "Confidential Information" to any Receiving Party. If Confidential Information is transmitted orally, Disclosing Party shall provide written notice within thirty (30) days indicating that such oral communication constitutes Confidential Information. Each Receiving Party agrees: (A) to take reasonable measures, but in any event, no less stringent measures than it uses to protect its own confidential information, to protect the Confidential Information of the Disclosing Party; (B) the Confidential Information shall remain the sole property of the Disclosing Party; (C) to restrict internal access to Confidential Information and only disseminate such Confidential Information on a need to know basis, provided that representatives who receive such shall be bound by the confidentiality obligations set forth in this Section; (D) to use Confidential Information solely for the purpose of the Award; and (E) except as otherwise provided in these Terms and Conditions, not disclose such Confidential Information to any third parties. These confidentiality obligations shall not apply to information which is: (A) information known to the Receiving Party prior to receipt from or on behalf of the Disclosing Party; (B) information that is disclosed to the Receiving Party by a third person who has a right to make such disclosure without any obligation of confidentiality to the Party seeking to enforce its rights under this Section; (C) information that is or becomes generally known in the trade without violation of this Agreement by the Receiving Party or is or becomes public knowledge without breach of this award letter; (D) information that is independently developed by the Receiving Party or its employees or affiliates without reference to the Disclosing Party's information, or (E) information that is authorized for release in writing by the Disclosing Party.

4. Institution Representations and Warranties.

(A) Institution represents and warrants to ASTRO to the best of its knowledge that the Terms and Conditions hereof do not and will not conflict with or violate any provision of the articles of incorporation, bylaws, limited partnership agreement or any similar instrument of Institution, as applicable, in any material way, and do not and will not conflict with, violate, or breach or constitute a default or require any consent under, any contractual obligation, policy or law by which Institution is bound, including any agreements with or policies applied to its researchers, employees, contractors, or other sources of funding.

(B) Institution certifies that neither it nor Principal Investigator: (i) is currently excluded, debarred, suspended or otherwise ineligible to participate in federal healthcare programs or in federal procurement or non-procurement programs; (ii) has been convicted of a criminal offense that is governed by 42 U.S.C. §1320a-7(a) related to the provision of health care items or services, but has not yet been excluded, debarred, suspended or otherwise declared ineligible; (iii) is debarred or subject to debarment under 21 U.S.C. §335(a); (iv) has been charged with a criminal offense that falls within the scope of 42 U.S.C. §§1320a-7(a), 1320a-7(b)(1)-(3); or (v) is otherwise subject to any restrictions or sanctions by the FDA.

5. Publications and Publicity.

(A) Publication and Presentations: ASTRO anticipates that all scientifically significant

results of the Research Proposal, whether negative or positive, will be published or otherwise publicly presented by Recipient. Any publication of research using the funding under the Award, unless otherwise requested by ASTRO, shall conspicuously acknowledge the support of the 2026 ASTRO Radiation Oncology Resident Fellowship and include the Grant Number provided in the Award Letter. Recipient shall also acknowledge the 2026 ASTRO Radiation Oncology Resident Fellowship as a funding source in presentations reporting on research supported by the Award. Recipient is expected to submit an abstract with results of the Research to the ASTRO Annual Meeting. Presentations or posters at major meetings must include the statement, "Supported by a grant from ASTRO."

(B) Release of Information: Copies of all publications, articles, abstracts, or presentations, whether written or oral, related to the Research Proposal shall be provided to ASTRO, subject to the rights of publishers or other third parties to the extent such rights have been communicated to ASTRO in writing by Recipient.

(C) License: ASTRO will be entitled to use, refer to, reproduce, and disseminate reprints of scientific, medical, and other published articles, subject to the rights of other third parties, directly relating to the Research Proposal or this Award, without any further compensation to any Recipient or any third party under applicable copyright law. As between ASTRO and Recipient, the intellectual property rights in and to the Work Product created by use of the Award shall remain with Recipient subject to the license below. Recipient hereby grants to ASTRO a non-exclusive, royalty-free, perpetual, irrevocable, worldwide right and license to use, copy, distribute, display, publish, publicize, modify and perform the Work Product for non-commercial purposes only, subject to the rights of other third parties in the Work Product.

(D) Publicity: Except as set forth in this section, neither party will use the name, symbols, or marks of the other party in any form of publicity without prior written consent of the other party; provided, however, that the Principal Investigator, Institution, and ASTRO may state factually on any of their websites and other materials the information authorized or approved per this Agreement. Furthermore, ASTRO may issue a press release and make public statements regarding the Award, the identity and general biographical information, any photographs or videos of the Recipient, Principal Investigator, and Institution and the general nature of the Award, its purpose, and the title and abstracts of any Research named as part of the Research Proposal, other published/printed information or materials (provided by the Principal Investigator) and Principal Investigator's activities on the ASTRO websites, social media platforms, periodic public reports, newsletters, news releases, publicly accessible databases of privately funded grant awards, or in any other format. If a Party wishes to make any other press or other announcement or release relating to this Agreement, the Research Proposal, or the Research occurring under this Agreement, that Party will discuss with, and obtain advance written agreement from the other Party regarding the content, form and manner of the announcement or release. If, and to the extent that the announcement or release is required to be made by the Party by law or by a stock exchange regulation, the Party will notify the other Party, Principal Investigator, and Institution, as applicable, in advance of the

announcement or release to the greatest extent possible.

6. Other Award Obligations.

(A) Recipient agrees to obtain all consents, authorizations, approvals and releases that may be necessary to undertake the Research and any materials prepared in connection with the Research. Recipient must obtain all relevant approvals [e.g. Institutional Review Board ("IRB") or Institutional Animal Care and Use Committee ("IACUC") approvals] for the conduct of human- or vertebrate animal-subject research before research can begin. Recipient must make these approvals available to ASTRO for review or audit upon request. ASTRO reserves the right to retract ASTRO funds from the Recipient if the Recipient conducts human or vertebrate animal subject research without having obtained relevant approvals from regulatory bodies such as an IRB or IACUC. Recipient will be solely responsible for any claims, actions, damages or expenses, including reasonable attorneys' fees, that may arise in any manner out of or in connection with Institution's failure to secure such consents, authorizations, approvals or releases or otherwise in connection with the Research.

(B) Principal Investigator is expected to send an electronic high-resolution, 300DPI, 4-color headshot photo (preferably 5x7 inches) and brief bio (~250 words) to ASTRO for use on the ASTRO website, *ASTROnews* and in other applicable ASTRO publications.

(C) To assist ASTRO with tracking the Principal Investigator's grant progress and career progression and impact of the ASTRO Grant program, Principal Investigator is expected to respond to ASTRO's related survey or email requests during or after the award period.

(D) Records: Recipient shall keep systematic and complete records on the receipt and disbursement of all Award funds and may not co-mingle any funds from other sources with the Award funds. Recipient shall retain all such records for a period of at least three (3) years after the expiration date of the Award Term, or for longer period(s) as may otherwise be required by applicable law. Recipient shall make these records available to ASTRO for review or audit upon request.

7. Termination.

(A) Termination

1. ASTRO reserves the right to terminate the Award immediately upon written notice if Recipient (i) is unable to complete the Research Proposal; (ii) terminates or suspends the Research Proposal; (iii) materially alters the Research Proposal; (iv) violates applicable laws or standards, or commits misconduct (including falsification, fabrication or plagiarism of data or results, omission of material data or results that occurs during the application process for, performance of or reporting on the Research Award, or other fraudulent or unlawful activity), as determined in ASTRO's discretion, (v) upon the insolvency, receivership, bankruptcy filing, or dissolution of the Institution or ASTRO, or (vi) upon

termination of the agreement between ASTRO and AstraZeneca.

2. In addition, ASTRO may terminate this Award for breach of the Award Letter or these Terms and Conditions, if such breach is not cured within thirty (30) days of receipt of written notice thereof or immediately if such breach is deemed material or not subject to cure in ASTRO's reasonable discretion. Use of the Award grant for prohibited expenses shall be considered a breach of these Terms and Conditions.

3. Furthermore, if the Principal Investigator departs from, or is otherwise no longer affiliated with, the Institution (each, an "Investigator Departure"), ASTRO reserves the right to terminate the Award with respect to any or all parties to the Award in its discretion.

4. ASTRO reserves the right to modify or terminate the amount of funds granted under the terms of the ASTRO Award upon advance written notice.

(B) Effects of Termination: In no event shall either Party be responsible for any lost profits or other lost opportunities arising from any early termination of this Award. In the event of early termination of the Award, the Institution shall promptly refund any unspent portion of the Award to ASTRO not associated with non-cancellable obligations in accordance with ASTRO's written instructions.

(C) Transition Assistance: In the event of an Investigator Departure, the Institution agrees to assist ASTRO and/or its designee, with the orderly transfer of any of its obligations under the Award to ASTRO or ASTRO's designee as expeditiously as possible.

(D) Survival: In addition to any provisions that by their nature survive expiration or termination of the Award, Section 1(C)-(D), 3-6, 7(C)-(D), and 8-9 shall survive the termination or expiration of the Award for any reason.

8. Indemnification and Liability.

(A) ASTRO Disclaimer: ASTRO IS A PASSIVE GRANTOR AND HEREBY DISCLAIMS ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, CONCERNING THE AWARD, THE RFP, OR THE RESEARCH PROPOSAL. UNDER NO CIRCUMSTANCE SHALL ASTRO BE LIABLE FOR, AND PRINCIPAL INVESTIGATOR AND SPONSORING INSTITUTION WAIVE ANY AND ALL LIABILITY AGAINST ASTRO FOR, ANY DAMAGES ARISING FROM OR IN RELATION TO THIS AWARD, THE RESEARCH PROPOSAL, OR THE USE OF THE RESEARCH RESULTS (WHETHER IN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, BY STATUTE, REGULATION OR OTHERWISE).

(B) Indemnification: Institution agrees to indemnify, defend, and hold harmless ASTRO, its officers, directors, personnel, and agents from and against any and all actual and alleged liabilities, damages, losses, claims, or expenses (including court costs and reasonable attorneys' fees), resulting from or arising in connection with the grant of this Award, the RFP or the performance of the Research Proposal, including without limitation, any claims brought by or on behalf of a third party such as subjects participating in any Research or activities related to the Research Proposal.

(C) Institution shall maintain insurance in adequate amounts and coverage to fulfill its and Principal Investigator's obligations hereunder. This provision shall survive the expiration or earlier termination, for any reason, of the Award Term.

9. Miscellaneous Provisions.

(A) Force Majeure: Neither Party shall be liable for any failure to perform any obligations under the Award if such failure results from causes beyond its reasonable control, including, but not limited to, war, sabotage, insurrection, riots, civil unrest, fires, flood, epidemics, earthquake, or other similar occurrences (including any mechanical, electronic, or communications failure, but excluding failure caused by Institution's own financial condition or negligence). If a Party is unable to perform any obligations under the Award pursuant to this provision, the affected Party shall give immediate written notice to the other party.

(B) Governing Law: This Agreement will be governed by and construed in accordance with the laws of Virginia, without giving effect to its principles or rules of conflict of laws to the extent such principles or rules would require or permit the application of the laws of another jurisdiction.

(C) Amendments: ASTRO may, with mutual written agreement with Institution, amend or add to these Terms and Conditions.

(D) Nature of Relationship: Nothing in these Terms and Conditions or the Award Letter shall constitute a partnership or joint venture or establish a relationship of agency between or among ASTRO and any Recipient. No employee of ASTRO or any Recipient shall be considered to be an employee of any of the others, and neither ASTRO nor Recipient shall enter into any contract or agreement with a third party that purports to obligate or bind any of the others.

(E) Waiver of Default or Breach: Failure to enforce the rights hereunder, regardless of the length of time such failure continues, shall not constitute a waiver of those or any other rights.

(F) Assignment: The Award Letter or Award may not be assigned or transferred without ASTRO's prior written consent, and any attempted transfer or assignment in violation of the Award Letter or these Terms and Conditions shall be void and of no force or effect.

(G) Entire Agreement: These Terms and Conditions, along with the Award Letter, the RFP, the Research Proposal, and the ASTRO Research Policies, all of which are incorporated by reference, constitute the full agreement of the parties as it relates to the Award. In the event of any inconsistency between the Terms and Conditions and the Award Letter, the terms of the Award Letter shall govern and control.

(H) Severability: Should any term or condition of the Award or these Terms and Conditions be determined to be unlawful by a court of law or adjudicative body with jurisdiction over the parties, the remainder will continue to remain in force and effect and shall be interpreted to best effect the original intentions of the parties.

The undersigned certify that they have read the above Terms and Conditions and are authorized to execute this Agreement to the Terms and Conditions on behalf of Institution, to obligate Institution to observe all of the Terms and Conditions contained in this Agreement, and in connection with this Agreement to make, execute, and deliver on behalf of the Institution all agreements, representations, receipts, reports, and other instruments of every kind.

By: _____

(ASTRO)

Date: _____

By: _____

(Institution)

Date: _____

ACKNOWLEDGEMENT:

I, the **Principal Investigator**, acknowledge that I have read and understood the terms and conditions of this Grant and provide my consent and agreement on the provisions that pertain to the Principal Investigator, including but not limited to the provisions that relate to submitting to ASTRO's Annual Meeting, as well as the permissions granted regarding ASTRO's use of the Work Product produced during the performance of the Research Proposal funded by the Award and of my name, likeness, and personal information as set forth in the Terms and Conditions. **I WAIVE ANY CLAIMS AGAINST ASTRO, ITS DIRECTORS, OFFICERS, EMPLOYEES OR AGENTS RELATED TO THE AWARD OR ANY PROJECT ASSOCIATED WITH THIS AWARD.**

By: _____

(Principal Investigator)

Date: _____

Attachments:

Schedule 1: Request for Proposal

Schedule 2: Research Proposal